09.04.2015 WILEX AG  DE000A11QVV0

DGAP-News: WILEX AG: WILEX subsidiary Heidelberg Pharma to present at two upcoming scientific conferences


 
DGAP-News: WILEX AG / Key word(s): Conference WILEX AG: WILEX subsidiary Heidelberg Pharma to present at two upcoming scientific conferences 09.04.2015 / 14:05 --------------------------------------------------------------------- PRESS RELEASE WILEX subsidiary Heidelberg Pharma to present at two upcoming scientific conferences Munich, Germany, 09 April 2015 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that its subsidiary Heidelberg Pharma GmbH will present at two upcoming scientific conferences. Antibody/Targeted Drug Conjugates (ATDC 2015) Professor Andreas Pahl, CSO of Heidelberg Pharma, will give a talk on "Improvement of the therapeutic index of amanitin-based ADCs" at the ATDC to be held in Porto, Portugal, on 13-15 April 2015. The talk is scheduled to take place on Tuesday, 14 April 2015 at 4:15 PM GMT in Session 7: ADC Development. Annual Meeting of the American Association for Cancer Research (AACR 2015) At the AACR in Philadelphia, Pennsylvania, taking place from 18 to 22 April 2015, a poster presentation regarding amanitin-based ADCs will be given by Dr Jan Anderl, Director Biochemistry and Cell Biology of Heidelberg Pharma, on Sunday, 19 April 2015, 1:00 PM - 5:00 PM EDT in Section 27. The abstract is available online on the AACR website: http://www.aacr.org. About WILEX and Heidelberg Pharma WILEX AG is a biopharmaceutical company which has a ready for partnering portfolio of antibody-based diagnostic and therapeutic Phase III product candidates for the detection and targeted treatment of clear cell renal cell carcinoma. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and provides pre-clinical drug discovery and development services. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / Symbol WL6. More information is available at www.wilex.com.
Contact                                  IR/PR support
WILEX AG                                 MC Services AG
Sylvia Wimmer                            Katja Arnold (CIRO)
Corporate Communications                 Executive Director
Tel.: +49 (0)89-41 31 38-29              Tel.: +49-89-210 228-40
Email: investors[at]wilex.com            Mobile: +49 (0)160 9360 3022
Grillparzerstr. 10, 81675 Munich,        Email: katja.arnold[at]mc-
Germany                                  services.eu

Business Development
Heidelberg Pharma GmbH
Dr. Marcel Linssen
CBO, Executive Vice President
Tel.: +49-(0) 6203 1009-40
Email: m.linssen[at]hdpharma.com
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments. --------------------------------------------------------------------- 09.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 10 81675 München Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: [email protected] Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 342623 09.04.2015


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1,90 3,67 7,31 8,49 1,75 18,51 9,86
EBITDA1,2 -10,35 -11,30 -9,60 -17,55 -24,83 -16,62 -20,33
EBITDA-Marge3 -544,74 -307,90 -131,33 -206,71 -1.418,86 -89,79
EBIT1,4 -10,75 -11,67 -10,14 -18,28 -25,63 -17,18 -21,21
EBIT-Marge5 -565,79 -317,98 -138,71 -215,31 -1.464,57 -92,82 -215,11
Jahresüberschuss1 -10,97 -11,67 -10,15 -18,37 -26,14 -19,70 -20,35
Netto-Marge6 -577,37 -317,98 -138,85 -216,37 -1.493,71 -106,43 -206,39
Cashflow1,7 -7,90 -9,98 -8,56 -17,89 -26,61 -8,57 -33,95
Ergebnis je Aktie8 -0,76 -0,41 -0,36 -0,61 -0,80 -0,44 -0,31
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
Heidelberg Pharma
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A11QVV 3,120 Halten 145,41
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -5,67
KBV KCV KUV EV/EBITDA
2,95 - 14,75 -5,29
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 20.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.04.2024 11.07.2024 10.10.2024 25.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-1,89% -5,40% -16,58% -32,76%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu WILEX AG  ISIN: DE000A11QVV0 können Sie bei EQS abrufen


Biotechnologie , A11QVV , HPHA , XETR:WL6